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1. Introduction
The Rome criteria are universally used as inclusion criteria in
pharmaceutical clinical trials and have therefore contributed
to testing of several irritable bowel syndrome (IBS)-specific
drugs. However, clinicians do not routinely use them because
they are complex and consequently difficult to remember.
Revised Rome diagnostic criteria for IBS and other functional
gastrointestinal disorders (FGIDs) were published in May 2016
[1]. These revised criteria, referred to as the Rome IV criteria,
replace the Rome III diagnostic criteria published 10 years
earlier. Changes to the diagnostic criteria raise a number of
questions both for clinicians and clinical researchers which will
be addressed in this review:
(1) Why revise the Rome III criteria now?
(2) Are the new criteria validated?
(3) What are the differences between Rome III and Rome
IV?
(4) How will these changes affect patient management?
2. Why revise the Rome III criteria now?
The Rome III criteria for IBS performed relatively well and were
widely accepted around the world; why change them now? In
fact only small changes, detailed below, were made in the IBS
diagnostic criteria. In part, they were made to address impor-
tant questions that have been raised about (1) the inclusion of
abdominal ‘discomfort’ as an alternative to pain [2], (2) the
most appropriate frequency of pain for IBS classification, and
(3) the way Rome III dealt with the comorbidity of constipa-
tion-predominant IBS (IBS-C) with functional constipation [3,4].
It is also important to update clinicians on the explosion of
new information on the pathophysiology of IBS (e.g. recogni-
tion that IBS is a brain-gut disorder and recognition of the role
of gut microflora, intestinal permeability, and inflammatory
signaling pathways to symptom development) and the new
treatment options (e.g. linaclotide, rifaximin, eluxadoline, and
low fermentable oligosaccharides, monosaccharides, and poly-
ols diets) that have come out in the last decade. Although the
changes to the IBS diagnostic criteria appear to be minor, they
will have a substantial impact on whether patients with less-
frequent symptoms are diagnosed IBS.
3. Validation of the Rome IV diagnostic criteria
A frequent criticism of the Rome III diagnostic criteria was that
they were not adequately validated; consequently, special
attention was paid to validating the Rome IV criteria prior to
publication [5]. The Rome Foundation sponsored a series of
studies to address different aspects of clinical validation which
are summarized below.
3.1. Evidence-based thresholds for symptom frequency
Diagnosis of IBS relies on symptoms (e.g. abdominal pain and
altered stool frequency) that also occur in healthy individuals;
these symptoms are not clinically significant unless they occur
at an abnormal frequency or intensity. However, the frequency
with which these symptoms occur in the population was not
known, and the thresholds included in the Rome III criteria
were based on expert opinion. To address this, the Rome
Foundation surveyed the frequency of occurrence of these
and other FGID symptoms in a nationally representative sam-
ple of 1665 US adults stratified by sex, age, and race [5].
Frequency histograms were computed for each symptom,
and the 90th percentile was chosen as the threshold for
clinical significance. The Rome working teams tasked with
revising the Rome diagnostic criteria were encouraged to
use these evidence-based thresholds, and this resulted in a
change in the frequency of abdominal pain required for IBS
diagnosis from 3 days per month to once per week.
3.2. Clinical validation
In the absence of a biological marker for IBS, symptom criteria
have been validated against one of two reference standards: a
negative endoscopy in a patient with abdominal pain or a
clinical diagnosis made by an experienced clinician following
any medical tests they required to exclude alternative diag-
noses [6]. The Rome IV criteria were validated against a hybrid
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of these two approaches; a total of 843 patients were recruited
by experienced gastroenterologists at nine academic medical
centers in three countries. Enrollment was targeted at patients
with established clinical diagnoses of the three most common
FGIDs: IBS, functional constipation, and functional dyspepsia.
The resulting sample included 427 patients with a primary
clinical diagnosis of IBS. Only after the completion of their
work-up and assignment of a diagnosis of IBS were patients
directed to a website to complete the Rome IV diagnostic
questionnaire plus the Rome III diagnostic questions for IBS.
These patients were required to have had a negative colono-
scopy within 5 years. This enabled us to estimate the sensitiv-
ity of the Rome IV criteria and to compare this to the
performance of Rome III in the same patients. Results are
shown in Table 1 where it can be seen that the Rome IV
criteria, by comparison to the Rome III criteria, correctly iden-
tify a somewhat lower percent of the patients diagnosed IBS
by expert clinicians (sensitivity), but they are less likely to
identify a person incorrectly as having IBS (specificity). Future
analyses will test whether the patients who would be identi-
fied by Rome III but not Rome IV have milder as well as less
frequent symptoms.
3.3. Performance of the Rome IV criteria in a
population-based sample
We next surveyed representative population samples of
approximately 2000 people from the United States, United
Kingdom, and English-speaking parts of Canada. The com-
bined final sample was 5931 individuals. This allowed us to
estimate the prevalence of IBS and the specificity of the
diagnostic criteria in an unbiased sample. The estimated pre-
valence of IBS was substantially lower when using the Rome IV
criteria (5.7%) as compared to the Rome III criteria (10.7%).
Specificity of the Rome IV criteria was greater than Rome III
(Table 1).
3.4. Test–retest reliability, understandability, and
translatability of Rome IV
The Rome IV diagnostic questionnaire resulted in the same
FGID diagnosis in 3/4 of patients over a 30-day period.
Assessment of understandability of the diagnostic question-
naire in an independent sample of 532 community subjects
stratified by age and educational level showed that more than
90% of individuals are likely to understand the questions with-
out difficulty, and understandability ratings were found to be
unrelated to age or education.
4. Specific changes to the Rome criteria and their
consequences
(1) Rome IV requires that abdominal pain occurs on aver-
age at least 1 day a week whereas only 3 days per
month were required in Rome III. This was the most
important factor accounting for a reduction in the esti-
mated prevalence of IBS from 11.7% for Rome III to
5.7% for Rome IV [5]. The comorbidity of IBS with func-
tional constipation, functional diarrhea, and functional
dyspepsia also contributed to misclassifications [5].
(2) Rome III allowed for a diagnosis of IBS on the basis of
abdominal ‘discomfort or pain’ whereas Rome IV requires
that patients have abdominal pain. The reasons for this
change are (a) ‘discomfort’ is an ambiguous term which is
interpreted by some patients as mild pain while others
regard it as qualitatively different symptom such as
urgency or bloating and (b) eliminating discomfort from
the criteria brings the diagnostic criteria into closer align-
ment with the US FDA’s guidance on evaluating IBS [2].
This change, requiring that pain be present, did not
contribute significantly to the reduction in prevalence
of IBS from Rome III to Rome IV.
(3) The temporal association between abdominal pain and
defecation or stool characteristics is less specific in Rome
IV. (a) In Rome III abdominal pain had to improve following
defecation whereas Rome IV only requires that abdominal
pain is associated in time with defecation, that is, occurring
either just before, during, or soon after defecation. (b) In
Rome III changes in the frequency or consistency of stools
had to follow the onset of abdominal pain, but in Rome IV
these symptoms just have to be temporally associated.
These changes in the temporal relationship between
pain and defecation were also found to have little impact
on the estimated prevalence of IBS.
In Rome III, the division of IBS into diarrhea-predominant
(IBS-D), IBS-C, mixed (IBS-M), and unspecified (IBS-U) subtypes
was based on the proportion of All bowel movements (BMs) that
were loose/watery or hard/lumpy. However, subsequent studies
showed that IBS subtyping was more reliable if based only on
the proportion of abnormal BMs that were loose/watery or hard/
lumpy [8] and this was adopted for Rome IV. In clinical practice
and for epidemiological studies, Rome IV assigns the IBS subtype
based on the patient’s perception of their predominant type of
abnormal stool consistency, resulting in a reduction in the num-
ber of patients who could not be classified (IBS-U) and the
number who were classified IBS-M by the Rome III criteria. This
affects clinical management because several medications are
approved by the FDA only for the treatment of IBS-C (e.g.
lubiprostone and linaclotide) while other medications are
approved only for IBS-D (e.g. rifaximin and eluxadoline); and
none are approved for the treatment of IBS-M or IBS-U.
Table 1. Diagnostic accuracy of Rome IV compared to Rome III criteria.
Test statistic Rome IV Rome III
Sensitivity .627 .731
Specificity .971 .931
Positive likelihood ratio (PLR)a 21.6 10.6
Negative likelihood ratio (NLR)b .384 .289
aThe PLR is defined as sensitivity/(1-specificity) [7]. Larger numbers reflect a
greater likelihood that a positive finding on the diagnostic test is associated
with true disease.
bThe NLR is defined as (1-sensitivity)/specificity. Smaller numbers reflect greater
likelihood that a negative finding on a diagnostic test is associated with
absence of disease.
5. Summary: implications of Rome IV for clinical
management of IBS
The Rome IV criteria for diagnosing IBS are more restrictive
than Rome III, primarily because they require more frequent
abdominal pain than the older criteria. A major strength is that
Rome IV criteria have been thoroughly validated and found to
have adequate sensitivity and excellent specificity, to be
reproducible over a 30-day interval, and the diagnostic ques-
tions are understandable to at least 90% of individuals of all
ages and educational backgrounds. These revisions in the
symptom criteria for IBS are likely to improve the performance
of the Rome criteria for selecting more homogeneous groups
of research subjects for clinical trials, but their use in routine
clinical practice may still be perceived as burdensome due to
their complexity. More widespread use of Rome IV criteria by
clinicians may however be on the horizon, as the Rome
Foundation is currently developing internet aides for easy
administration and interpretation of the Rome IV criteria at
the point of care. A limitation of the Rome IV criteria is that
they remain exclusively based on symptom reports and a
limited number of tests to exclude other diseases. This may
gradually change as research efforts to identify biomarkers for
IBS pay off, but at present there are no biomarkers that per-
form better than the Rome symptom criteria [9].
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